Authors

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

The End of the Rebate Era? What HR Leaders and Pharmacy Consultants Need to Know About Biosimilars

As the availability and utilization of ultra-high-cost, long-term specialty products such as GLP-1s and cell and gene therapies grows, HR decision-makers and pharmacy consultants must embrace a more value-oriented mindset where they can.

2025 Pharma Forecast: Four Pivotal Trends Revolutionizing Market Access Strategies

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

A Brave New World: Implications of the IRA on Brand Strategy

Amid converging pharma pricing trends, such as those triggered by the Inflation Reduction Act, companies must adopt novel operational practices and strategic approaches in line with new parameters for success across a product’s lifecycle.

The Evolution of Healthcare Communication: Bridging the HCP-Patient Divide

Key trends in healthcare communication to build trust between healthcare providers and their patients.

The AI Force Multiplier: How AI Is Leveling the Playing Field for Small and Mid-Size Biotech

By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI platforms are leveling the playing field by enabling lean teams to de-risk clinical strategy, strengthen fundraising narratives, and make faster, more confident decisions across the development lifecycle.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Strategic advantage: Optichannel engagement drives ROI across the product lifecycle

Your Phase III Clinical Protocol Is Your Initial Product Launch

How demand-driven development will help new products be more successful.

Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint

Recent policy shifts in these two influential health technology assessment markets signal a broader regional move toward faster, more innovation-friendly access frameworks.

Navigating Cross-Border Pharma Deals: Key Trends and Lessons Out of China

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Transforming Life Sciences R&D: The Business Case for AI

Webinar Date/Time: Thu, Aug 14, 2025 3:30 PM EDT

JCA vs. Reality: Europe’s Push for Clinical Harmonization

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

Taking Advantage of ‘Hidden Gem’ Talent Hubs

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Navigating the EU’s Joint Clinical Assessment

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

Pharma Forecasting: Key Markets Investors Can’t Ignore

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Driving Field Excellence with AI-Enhanced Rep Support

JCA vs. Reality: Europe’s Push for Clinical Harmonization

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

The Situation We Faced: Aaron Cowley, CSO, Recipharm Advanced Bio, Discusses Vision to Cut Biomanufacturing Timelines, Transform Continuous Manufacturing

A new unified approach to process analytical technologies from Recipharm Advanced Bio aims to replace fragmented, off-line testing with integrated real-time analytics—cutting development and release timelines by up to 50% while aligning with FDA-backed continuous manufacturing initiatives and a multibillion-dollar global PAT market opportunity.

Pharmaceutical Executive Daily: FDA Expands Approval for Arexvy

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses to cover healthcare costs, the FDA expands the approved age indication for GSK's RSV vaccine Arexvy to adults aged 18 to 49 at increased risk, and a new commentary argues that agentic AI is positioned to fundamentally reshape commercial operations in life sciences.

AI-Enabled Benchmarking: Transforming Performance Measurement for Pharma Brands

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

JCA vs. Reality: Europe’s Push for Clinical Harmonization

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

Driving Field Excellence with AI-Enhanced Rep Support

Are DTC Programs Treating a Symptom or Cause of High Drug Prices?

Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.